Emerald Advisers, LLC Vericel Corp Transaction History

Emerald Advisers, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 28, 2020	SELL	$14.68 - $19.12 $248,972 - $324,275	-16,960 Closed	0 $0
Q2 2020 Jul 28, 2020	SELL	$8.5 - $15.82 $4.52 Million - $8.41 Million	-531,653 Reduced 96.91%	16,960 $234,000
Q1 2020 Apr 30, 2020	SELL	$7.25 - $19.22 $269,381 - $714,138	-37,156 Reduced 6.34%	548,613 $5.03 Million
Q4 2019 Jan 29, 2020	SELL	$13.77 - $19.2 $2.35 Million - $3.28 Million	-171,020 Reduced 22.6%	585,769 $10.2 Million
Q3 2019 Oct 31, 2019	SELL	$14.93 - $19.83 $320,158 - $425,234	-21,444 Reduced 2.76%	756,789 $11.5 Million
Q2 2019 Jul 31, 2019	BUY	$15.01 - $18.89 $5.43 Million - $6.83 Million	361,636 Added 86.81%	778,233 $14.7 Million
Q1 2019 May 01, 2019	BUY	$16.23 - $20.29 $6.76 Million - $8.45 Million	416,597 New	416,597 $7.3 Million

277

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.73B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.